Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Phathom Pharmaceuticals, Inc is a biotechnology business based in the US. Phathom Pharmaceuticals shares (PHAT) are listed on the NASDAQ and all prices are listed in US Dollars. Phathom Pharmaceuticals employs 25 staff and has a market cap (total outstanding shares value) of USD$963.3 million.
|Latest market close||USD$38.08|
|52-week range||USD$22.06 - USD$55.14|
|50-day moving average||USD$42.5056|
|200-day moving average||USD$38.0688|
|Wall St. target price||USD$51.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.0847|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||3.48%|
|1 month (2020-12-16)||-17.29%|
|3 months (2020-10-15)||-2.33%|
|6 months (2020-07-15)||21.82%|
|1 year (2020-01-15)||11.09%|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-35.79%|
|Return on equity TTM||-8828.78%|
|Market capitalisation||USD$963.3 million|
TTM: trailing 12 months
There are currently 665,710 Phathom Pharmaceuticals shares held short by investors – that's known as Phathom Pharmaceuticals's "short interest". This figure is 12.6% down from 761,428 last month.
There are a few different ways that this level of interest in shorting Phathom Pharmaceuticals shares can be evaluated.
Phathom Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Phathom Pharmaceuticals shares currently shorted divided by the average quantity of Phathom Pharmaceuticals shares traded daily (recently around 70820.212765957). Phathom Pharmaceuticals's SIR currently stands at 9.4. In other words for every 100,000 Phathom Pharmaceuticals shares traded daily on the market, roughly 9400 shares are currently held short.
However Phathom Pharmaceuticals's short interest can also be evaluated against the total number of Phathom Pharmaceuticals shares, or, against the total number of tradable Phathom Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Phathom Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Phathom Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0545% of the tradable shares (for every 100,000 tradable Phathom Pharmaceuticals shares, roughly 55 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Phathom Pharmaceuticals.
Find out more about how you can short Phathom Pharmaceuticals stock.
We're not expecting Phathom Pharmaceuticals to pay a dividend over the next 12 months.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.